

## INFORMATIONAL LETTER NO. 2564-MC-FFS

**DATE:** March 8, 2024

**TO:** All Iowa Medicaid Medical Providers

**APPLIES TO:** Managed Care (MC), Fee-for-Service (FFS)

**FROM:** Iowa Department of Health and Human Services (HHS), Iowa Medicaid

**RE:** Avastin® (bevacizumab) Billing

**EFFECTIVE:** January 1, 2023

\*\*\*This letter **replaces** previous guidance in [Informational Letters \(ILs\) 2143, 2264, 2491](#)<sup>1\*\*\*</sup>

Avastin® (bevacizumab) was approved by the U.S. Food and Drug Administration (FDA) in 2004 to treat metastatic colon cancer. Based on published reports and widespread clinical use; including the support of the American Academy of Ophthalmology, there is compelling evidence of bevacizumab’s safety and efficacy for off-label intravitreal use in choroidal neovascularization in age-related macular degeneration (AMD), proliferative diabetic retinopathy, neovascular glaucoma, diabetic macular edema (DME), retinal and iris neovascularization and macular edema following branch and central retinal vein occlusions.

The following guidance applies only to Avastin® (bevacizumab) and **does not** apply to biosimilars of Avastin®.

HCPCS	Definition	NDCs	Billing Notes
C9257	Injection, bevacizumab, 0.25 mg	50242006001 50242006101 50242006010 (NDC inactivated 1/31/2023) 50242006110 (NDC inactivated 2/28/2023)	<ul style="list-style-type: none"> <li>▪ 1 unit = 0.25 mg</li> <li>▪ <u>Ophthalmic dosing:</u> <ul style="list-style-type: none"> <li>▪ 5 units = 1.25 mg per eye</li> </ul> </li> </ul>

<sup>1</sup> <https://secureapp.dhs.state.ia.us/IMPA/Information/Bulletins.aspx>

HCPCS	Definition	NDCs	Billing Notes
<b>J9035</b>	Injection, bevacizumab, 10 mg	50242006001 50242006101 50242006010 (NDC inactivated 1/31/2023) 50242006110 (NDC inactivated 2/28/2023)	<ul style="list-style-type: none"> <li>▪ 1 unit = 10 mg</li> <li>▪ <u>Ophthalmic dosing:</u> <ul style="list-style-type: none"> <li>▪ 1 unit = 1.25 mg per eye</li> </ul> </li> </ul>
<b>J7999*</b>	Compounded drug, not otherwise classified	50242006001 50242006101	<ul style="list-style-type: none"> <li>▪ J7999 should be used to report compounded drugs that have been approved by the FDA, but do not have a product-specific HCPCS Level II code assigned. <ul style="list-style-type: none"> <li>▪ 1 unit = 1.25 mg</li> </ul> </li> <li>▪ \$76.00 per eye, per calendar month</li> </ul>

\*J7999 is an unspecified code (i.e., “dump code”). Rate of \$76 per unit will need to be applied when the claim is manually priced.

Note: If using an individual dose of Avastin® (bevacizumab) prepared by an FDA-registered 503B outsourcing facility, **submit the NDC of the active medication** (Avastin®). Outsourcing facilities may, but are not required to, assign NDCs to their finished compounded human drug products, but these NDCs are not eligible for rebate under the Medicaid Drug Rebate Program.

As a reminder, per [IL 2475-MC-FFS<sup>2</sup>](#), effective for dates of service on and after January 1, 2017, providers and suppliers are required to report the **JW** modifier on all claims that bill for drugs and biologicals with unused and discarded amounts from single-dose containers or single-use packages. Effective for dates of service on and after July 1, 2023, providers and suppliers are required to report the **JZ** modifier on all claims that bill for drugs from single-dose containers when there are no discarded amounts.

For Fee-for-Service (FFS) and Managed Care Organization (MCO) prior authorization (PA) requirements, the provider should contact the appropriate payor.

If you have questions, please contact Iowa Medicaid Provider Services or the appropriate MCO:

**Iowa Medicaid Provider Services:**

- Phone: 1-800-338-7909
- Email: [imeproviderservices@dhs.state.ia.us](mailto:imeproviderservices@dhs.state.ia.us)

<sup>2</sup> <https://secureapp.dhs.state.ia.us/IMPA/Information/ViewDocument.aspx?viewdocument=f7bdaf0e-08a8-4cd0-810a-8a3b28744eb4>



**Iowa Total Care:**

- Phone: 1-833-404-1061
- Email: [providerrelations@iowatotalcare.com](mailto:providerrelations@iowatotalcare.com)
- Website: <https://www.iowatotalcare.com>

**Molina Healthcare of Iowa:**

- Phone: 1-844-236-1464
- Email: [iaproviderrelations@molinahealthcare.com](mailto:iaproviderrelations@molinahealthcare.com)
- Website: <https://www.molinahealthcare.com/providers/ia/medicaid/home.aspx>
- Provider Portal: <https://www.availity.com/molinahealthcare>

**Wellpoint Iowa, Inc. (formerly Amerigroup Iowa, Inc.):**

- Phone: 1-833-731-2143
- Email: [ProviderSolutionsIA@wellpoint.com](mailto:ProviderSolutionsIA@wellpoint.com)
- Website: <https://www.provider.wellpoint.com/iowa-provider/home>